Abivax S.A.’s Price-to-Book Ratio at a glance
Abivax S.A. reports price-to-book ratio of 10.5x for Dec 2024. The prior period recorded 2.2x (Dec 2023). Year over year the metric moved +8.34 (+386.7%). The rolling three-period average stands at 9.7x. Data last refreshed Dec 7, 2025, 1:32 AM.
Latest reading
10.5x · Dec 2024
YoY movement
+8.34 (+386.7%)
Rolling average
9.7x
Current Price-to-Book Ratio
10.5x
+8.34
+386.7%
Rolling average
9.7x
Latest Value
10.5x
Dec 2024
YoY Change
+8.34
Absolute
YoY Change %
+386.7%
Rate of change
3-Period Avg
9.7x
Smoothed
Narrative signal
Abivax S.A.’s price-to-book ratio stands at 10.5x for Dec 2024. Year-over-year, the metric shifted by +8.34, translating into a +386.7% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-book ratio shapes Abivax S.A.'s story
As of Dec 2024, Abivax S.A. reports price-to-book ratio of 10.5x. Monitor price-to-book trends to gauge how investors value tangible assets and equity on the balance sheet.
Capital-intensive industries
Banks, insurers, and industrials rely on P/B to judge returns on equity relative to book value.
Reading discount or premium
Ratios below 1.0 signal the market values equity below book, which could mean undervaluation or weak profitability.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
100%
Operating Margin
-1,718.2%
Net Profit Margin
-1,633.1%
Return on Equity
-434.3%
Return on Assets
-85.9%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Abivax S.A. (ABVX) FAQs
Answers tailored to Abivax S.A.’s price-to-book ratio profile using the latest Financial Modeling Prep data.
What is Abivax S.A.'s current price-to-book ratio?
As of Dec 2024, Abivax S.A. reports price-to-book ratio of 10.5x. This reading reflects the latest filings and price data for ABVX.
How is Abivax S.A.'s price-to-book ratio trending year over year?
Year-over-year, the figure shifts by +8.34 (+386.7%). Pair this context with revenue growth and free cash flow signals to gauge momentum for ABVX.
Why does price-to-book ratio matter for Abivax S.A.?
Price-to-book compares market value with book value of equity, highlighting balance sheet-driven valuation. For Abivax S.A., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Abivax S.A.'s price-to-book ratio above its recent average?
Abivax S.A.'s rolling three-period average sits at 9.7x. Comparing the latest reading of 10.5x to that baseline highlights whether momentum is building or fading for ABVX.
How frequently is Abivax S.A.'s price-to-book ratio refreshed?
Data for ABVX was last refreshed on Dec 7, 2025, 1:32 AM and updates automatically every 24 hours, keeping your valuation inputs current.